8-K filing — GLAUKOS Corp (GKOS)
Filed: 2026-11-06 AccNo: 0001193125-26-450710 Size: 16 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy
Glaukos reports positive Phase 4 results for its iDose TR therapy, demonstrating superior efficacy over standalone cataract surgery.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Ginkgo Bioworks Reports Q3 2026 Financial Results and First Autonomous Lab Sale
Ginkgo Bioworks announced its third-quarter 2026 financial results, highlighting the first sale of its autonomous lab platform and reaffirmed cash-burn guidance.
Glaukos Insider Executes Significant Share Sale
A Glaukos Corporation insider has sold shares valued at approximately $10.6 million, as disclosed in a recent SEC filing.
BDX Gears Up to Report Q4 Results: How to Play the Stock?
Becton Dickinson (BDX) is set to report Q4 fiscal 2026 results on Nov. 5, with EPS expected to grow 2.53% despite a 13% revenue decline. While Medical Essentials and Interventional segments show strength, China market challenges and a 200-basis-point Alaris revenue headwind are expected to weigh on quarterly performance. The company has a positive Earnings ESP of +0.21% and Zacks Rank #2, suggesting an earnings beat is unlikely despite historical performance.
Glaukos Announces Participation in Upcoming Investor Conferences
Glaukos Corporation management is scheduled to participate in the Stifel Healthcare Conference and the Jefferies Global Healthcare Conference in November 2026.
Ginkgo Bioworks Director Catherine Cifuentes-Rojas Releases Biotherapeutics Go/No-Go Checklist
Dr. Catherine Cifuentes-Rojas, Director and Lead for Genetic Medicines and Biologics at Ginkgo Bioworks, has published a data-driven checklist designed to assist R&D teams in evaluating early-stage biotherapeutic programs.